Tadalafil appartiene alla classe degli inibitori selettivi della fosfodiesterasi di tipo 5, con un profilo farmacocinetico caratterizzato da un’emivita terminale di circa diciotto ore. Dopo somministrazione orale viene assorbito rapidamente e raggiunge concentrazioni plasmatiche massime in due ore. La biotrasformazione avviene principalmente tramite CYP3A4 con formazione di metaboliti inattivi, escreti in prevalenza con le feci. L’elevato legame alle proteine plasmatiche (>90%) assicura una distribuzione stabile. Nei confronti delle altre molecole della stessa classe, cialis compresse italia è noto per la durata prolungata dell’attività farmacologica.

Kongressystem (mv_fms4)

PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
2009-05-10
SESSION 01: HPV PROPHYLACTIC VACCINES, CLINICAL ASPECTS
13.30-14.05
HPV VACCINATION AND PUBLIC HEALTH: OPPORTUNITY AND
CHALLENGE
J Paavonen
14.05-14.18
IMPACT OF HPV VACCINATION DEPENDS ON EFFECTIVE STRATEGY
M Lehtinen
14.18-14.29
IMMUNE RESPONSE AFTER PRIMARY VACCINATION COURSE: A
COMPARATIVE TRIAL OF TWO HPV PROPHYLACTIC VACCINES
M H Einstein, on behalf of the HPV-010 Study Group
14.29-14.40
LONG-TERM EFFICACY OF A PROPHYLACTIC HUMAN PAPILLOMAVIRUS
TYPE 16 VACCINE
A Rowhani - Rahbar, C Mao, FB Alvarez, JT Bryan, SE Hawes, JP Hughes, NS Weiss, LA
Koutsky
14.40-14.51
QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE EFFICACY AGAINST
LOW-GRADE GENITAL DISEASE
J Dillner, for the GARDASIL phase III investigators
14.51-15.02
IMPUTED GLOBAL VACCINATION BENEFIT BY KEY RISK PREDICTORS
A Rodriguez, Ar Kreimer, S Wacholder, P Gonzalez, M Schiffman, C Porras, D Solomon, R
Herrero, A Hildesheim
15.02-15.13
WHO RECOMMENDATIONS: USE OF HPV VACCINES IN NATIONAL
IMMUNIZATION PROGRAMMES
KL Irwin, J Hombach, MT Aguado
15.13-15.24
QUADRIVALENT HPV VACCINE EFFFICACY AGAINST MALE GENITAL
DISEASE AND INFECTION
A Giuliano, J Palefsky
15.24-15.35
IMPACT OF HPV6/11/16/18 VACCINE ON ABNORMAL PAP TESTS AND
PROCEDURES
S - O Olsson, J Paavonen
15.35-15.46
MISCARRIAGE RISK IN TWO RANDOMIZED CONTROLLED TRIALS OF HPV
VACCINE
S Wacholder, B Chen, A Wilcox, G Macones, P Gonzalez, B Befano, A Hildesheim, A
Rodriguez, D Solomon, R Herrero, M Schiffman, for CVT Group
15.46-15.57
HPV VACCINATION UPTAKE AND REGISTRATION OF HPV VACCINATION
IN SWEDEN
P Sparén
SESSION 02: THERAPEUTIC VACCINES AND IMMUNOMODULATION
13.30-14.05
THE SPONTANEOUS HPV-SPECIFIC IMMUNE RESPONSE AS A GUIDE FOR
IMMUNOTHERAPY
S H van der Burg
14.05-14.16
IMMUNOTHERAPY OF VIN WITH IMIQUIMOD FOLLOWED BY PDT OR
VACCINATION
P L Stern, S Daayana, E Elkord, U Winters, H Kitchener
14.16-14.27
POISED HPV16-SPECIFIC T-CELLS IN CERVICAL CARCINOMA AND
DRAINING LYMPH NODES
P J de Vos van Steenwijk, M Heusinkveld, TH Ramwadhdoebe, AM van der Hulst, SJ
Piersma, R Goedemans, GG Kenter, SH van der Burg
14.27-14.38
REGRESSION IS ASSOCIATED WITH CD8 RESPONSES TO HPV 16 E6
M Nakagawa, S Gupta, H Coleman, M Sellers, J Banken, W Greenfield
14.38-14.49
VIRAL VECTOR-BASED PRIME-BOOST IMMUNIZATIONS: A POSSIBLE
INVOLVEMENT OF T-CELL COMPETITION
T Daemen, A. de Mare, A.J.A. Lambeck, J. Regts, G.M. van Dam, H.W. Nijman, H. Snippe, J
Wilschut
14.49-15.00
IFN-KAPPA IS ABOLISHED BY CERVICAL CANCER-ASSOCIATED HUMAN
PAPILLOMAVIRUS TYPE16
B Rincon - Orozco, G Halec, F Bosch, F Roesl
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
15.00-15.11
GENITAL IMMUNIZATION WITH HPV PSEUDOVIRIONS INDUCES GENITAL
CD8+ T CELLS
N J Cuburu, RC Kines, J Roberts, J Nicewonger, BS Graham, CB Buck, D Lowy, J Schiller
15.11-15.22
DMXAA ENHANCES THERAPEUTIC HPV VACCINE-INDUCED CTL
RESPONSES AND ANTITUMOR EFFECTS
S Peng, A Monie, Cf Hung, T.-C. Wu
15.22-15.33
NOVEL IMMUNOTHERAPY TO INDUCE E7-SPECIFIC CTL IN MURINE
GENITAL MUCOSA
L Decrausaz, M Duc, Ar Goncalves, M Bobst, N Zosso, D Nardelli - Haefliger
15.33-15.44
HPV-16 E5 DOWN-REGULATES MHC I AND CONTRIBUTES TO VIRAL
IMMUNOEVASION
M S Campo, S Man, MS Cortese, K Smith, E Dornan
15.44-15.55
REGULATION OF LANGERHANS CELL NUMBER ACROSS HPV GENERA
M Hibma, C-M Leong, J Doorbar, H-S Yoon
2009-05-11
SESSION 03: EPIDEMIOLOGY OF HPV-ASSOCIATED DISEASES
08.30-09.05
GLOBAL PERSPECTIVE ON HPV AND HPV-ASSOCIATED DISEASES
S Franceschi, G Clifford, J Ferlay, S Vaccarella, HR Shin
09.05-09.16
TIME TRENDS IN THE HPV TYPES DISTRIBUTION IN CERVICAL CANCER
L Alemany
09.16-09.27
THE ROLE OF CO-FACTORS IN CERVICAL CANCER IN EPIC COHORT
E ROURA, N TRAVIER, C GONZALEZ, F BOSCH, X CASTELLSAGUE
09.27-09.38
IMMUNITY-RELATED CANDIDATE GENES AFFECTING CERVICAL CANCER
SUSCEPTIBILITY
E Ivansson, J Magnusson, I Gustavsson, L Steiner, P Magnusson, H Erlich, U Gyllensten
09.39-09.49
REDUCED RISK OF CERVICAL AND VULVAR CANCERS ASSOCIATED
WITH ALLERGIES
L G Johnson, s Schwartz, PL Porter, D Galloway, MM Madeleine
09.49-10.00
GENE POLYMORPHISMS ASSOCIATED WITH CERVICAL CANCER IN
SWEDEN
F A Castro, K. Haimila, I. Sareneva, M Schmitt, J Bermejo, N. Kunkel, R. Kumar, A. Försti, L
Kjellberg, G. Hallmans, M Lehtinen, K. Hemminki, M Pawlita
SESSION 04: CERVICAL SCREENING & COLPOSCOPY
11.00-11.10
INACCURACY OF COLPOSCOPIC-DIRECTED BIOPSY
RG Pretorius
11.10-11.20
NEGATIVE SCREENING NOR COLPOSCOPY PROVIDES ABSOLUTE
REASSURANCE AGAINST CERVICAL CANCER
P Castle, A Rodriguez, Rd Burk, R Herrero, A Hildesheim, D Solomon, M Sherman, J
Jeronimo, M. Alfaro, J. Morales, D. Guillen, M. Hutchinson, S Wacholder, M Schiffman
11.20-11.30
PAP SMEAR COLLECTION POTENTIATES HPV16 INFECTION IN A
MACAQUE MODEL
D Lowy, J Roberts, Rc Kines, H Katki, C Thompson, Cb Buck, M Bernardo, P Choyke, J
Schiller
11.30-11.40
THE ACCURACY OF COLPOSCOPIC BIOPSY: DATA FROM THE GARDASIL
TRIALS
M Stoler, A Ferenczy, D Ferris, G Perez, E Joura, R Haupt, H Sings, S Lu, P James, M
Vichnin
11.40-11.50
CERVIX CANCER SUBSEQUENT TO ALTERNATIVE SCREENING
METHODS: PROSPECTIVE RANDOMISED STUDY
P Nieminen, A Arun Pokhrel, M Hakama, L Kotaniemi - Talonen, A Anttila
11.50-12.00
RISK OF CERVICAL CANCER AND MANAGEMENT OF ABNORMAL PAP
SMEARS
L Silfverdal, L Kemetli, B Andrae, P Sparén, W Ryd, J Dillner, B Strander, S Törnberg, S
Törnberg, S Törnberg
12.00-12.10
AUDIT OF THE FINNISH SCREENING PROGRAM FOR CERVICAL CANCER
S Lönnberg, P Nieminen, A Anttila
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
12.10-12.20
EXTENSION AND PROCESS PERFORMANCE OF EUROPEAN CERVICAL
CANCER SCREENING PROGRAMMES
G Ronco, M Van Ballegooijen, N Becker, A Chil, F Muriel, P Giubilato, J Kurtinaitis, L
Lancucki, E Lynge, A Morais, M O'Reilly, P Sparen, O Suteu, M Rebolj, P Veerus, M Zakelji,
A Anttila
12.20-12.30
NBI COLPOSCOPY IS CRITICAL TO SELECT CIN3 FROM CIN2/3 PATIENTS
T Fujii, M Nakamura, T Iwata, A Ohno, H Nishio, M Saito, D Aoki
SESSION 05: PENILE AND ANAL DISEASES
14.00-15.00
HPV 6/11 DISEASE – EPIDEMIOLOGY, TREATMENT, AND PREVENTION
C J N Lacey
15.00-15.10
ACQUISITION AND CLEARANCE OF ANAL HPV AMONG WOMEN
M T Goodman, YB Shvetsov, P Thompson, LR Wilkens, BY Hernandez
15.10-15.20
ANAL HPV-16 DNA VIRAL LOAD AND NEOPLASIA AMONG MSM
C Wang, Q Feng, S Cherne, D Kenney, N Kiviat, Se Hawes
15.20-15.30
WORLDWIDE HPV CONTRIBUTION AND GENOTYPE DISTRIBUTION IN
INVASIVE PENILE CANCER
C Miralles, on behalf of the HPV VVAPO study group
SESSION 06: EPIDEMIOLOGY OF HPV INFECTION
16.00-16.35
ASPECTS OF HPV NATURAL HISTORY THAT INFORM VACCINATION AND
SCREENING
M Schiffman
16.35-16.46
RATE OF AND RISKS FOR SECOND INFECTIONS IN YOUNG WOMEN
A B Moscicki, Y Ma, S Farhat, S Shiboski
16.46-16.57
HPV IN OLDER WOMEN IS ASSOCIATED WITH NEW SEXUAL PARTNERS
H Trottier, S Ferreira, JCM Prado, JS Sobrinho, MC Costa, LL Villa, E Franco
16.57-17.08
GENETIC VARIANTS IN HPV-BINDING GENES AND RISK FOR HPV
PERSISTENCE
A Hildesheim, P Gonzalez, K Yu, C Porras, M Safaeian, A Rodriguez, J Li, M Sherman, C
Bratti, M Schiffman, S Wacholder, Rd Burk, S Chanock, R Herrero, S Wang
17.08-17.19
ONE HPV VIRUS, ONE LESION AS DETERMINED BY LCM/PCR
TECHNOLOGY
W Quint, A Molijn, B Colau, M van der Sandt, D Jenkins
17.19-17.30
NATURAL HISTORY OF HPV INFECTIONS AND VULVAR DISEASE
DEVELOPMENT
E Joura, R Insinga, H Sings, R Haupt, S Garland
SESSION 07: EXPERIMENTAL THERAPEUTICS
08.30-08.41
IMPACT OF TUMOR-INFILTRATING HPV-SPECIFIC T-REGULATORY CELLS
IN CERVICAL CANCER PATIENTS
Sj Piersma, Jm van der Hulst, Es Jordanova, Gg Kenter, Sh van der Burg
08.41-08.53
CLEARANCE OF HPV IN VIN: NORMALIZATION OF IMMUNOCOMPETENT
CELL COUNTS
L Blok, A Terlou, A Kleinjan, M Van Seters, C Heijmans - Antonissen, I Beckmann, M Van
Beurden, T Helmerhorst
08.53-09.05
IMMUNE THERAPEUTIC STRATEGIES FOR PREINVASIVE HPV DISEASE
CL Trimble
09.05-09.16
HPV PSEUDOVIRIONS AS VEHICLES FOR GENETIC IMMUNIZATION AND
GENE THERAPY
RC Kines, BS Graham, J Nicewonger, TR Johnson, J Roberts, CB Buck, D Lowy, J Schiller
09.16-09.27
REQUIREMENTS FOR EFFECTIVE IMMUNOTHERAPY OF CHRONIC VIRAL
INFECTION IN SKIN
GR Leggatt, J Zhong, S Mattarollo, X Liu, R De Kluyver, S Fiorenza, J Zhou, U Hadis, N
Warif, A Rahimpour, J Broom, I Frazer
09.27-09.38
T-CELL IMMUNITY OF THERAPEUTIC VACCINATED PATIENTS
CORRELATES WITH CLINICAL RESPONSES
MJP Welters, GG Kenter, APG Vloon, MJG Löwik, TMA Berends - van der Meer, F
Essahsah, JW Drijfhout, ARPM Valentijn, LM Fathers, J Oostendorp, GJ Fleuren, CJM
Melief, SH van der Burg
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
09.38-09.49
HPV16 IMMUNE ESCAPE IS INDUCED BY THE MINOR CAPSID PROTEIN
A. Raff, L Fahey, D Da Silva, Wm Kast
09.49-10.00
COMBINED THERAPY WITH AD-LIGHT AND HPV16E6E7-VRP INDUCES
SIGNIFICANT TUMOR REGRESSION
S Kanodia, D Da Silva, T Karamanukyan, L Bogaert, YX Fu, WM Kast
SESSION 08: VIRUS LIFE CYCLE
11.00-11.11
LOW- AND HIGH-RISK HUMAN PAPILLOMAVIRUS E7 PROTEINS
REGULATE P130 DIFFERENTLY
A Roman, L Barrow - Laing
11.11-11.22
HPV E7 INDUCES G2 ARREST FOLLOWING S-PHASE IN DIFFERENTIATED
KERATINOCYTES
N.S. Banerjee, L.T. Chow, N.J. Genovese, H.K. Wang, T.R. Broker
11.22-11.33
HPV-31 REQUIRES ATM ACTIVITY FOR REPLICATION IN
DIFFERENTIATING CELLS
C Moody, L Laimins
11.33-11.44
GENOMIC INSTABILITY INDUCED BY THE HIGH RISK HUMAN
PAPILLOMAVIRUSES
M Ustav, T Laos, H Isok - Paas, E Ustav, M Kadaja
11.44-11.55
ROLE OF L2 CYSTEINES IN INFECTION AND NEUTRALIZATION BY RG-1
R Roden, S Jagu, B Karanam, P Day, R Gambhira
11.55-12.06
HPV16 L2 INTRAMOLECULAR DISULFIDE BOND IS CRITICAL FOR
INFECTIVITY
M Ozbun, S Campos
12.06-12.17
TISSUE TROPISM OF CANINE PAPILLOMAVIRUS IS DETERMINED INVIVO
AND KERATINOCYTE-INDEPENDENT
H Yuan, D Zhou, M Marko, J Wang, R Tucker, X Liu, R Schlegel
12.17-12.28
TOWARDS AN UNDERSTANDING OF PAPILLOMAVIRUS LATENCY USING
THE ROPV MODEL
G Maglennon, P McIntosh, J Doorbar
SESSION 09: VIRAL GENOME REPLICATION AND ANTIVIRALS
15.00-15.30
ANALYSIS OF PAPILLOMAVIRUS INITIATION OF DNA REPLICATION
A Stenlund, S Schuck
16.00-16.11
DRUG-LIKE COMPOUNDS THAT INHIBIT HPV-16 E6
E Androphy, J Baleja, J Cherry
16.11-16.22
HPV-11 E1 RELOCALIZES MRE11 AND NBS1 TO REPLICATION CENTERS
L.T. Chow, L.L. Dao, J.H. Yu, T.R. Broker
16.22-16.33
MITOGEN-ACTIVATED PROTEIN KINASES ARE CRUCIAL FOR HPV DNA
AMPLIFICATION
J.H. Yu, T.R. Broker, B.Y. Lin, H.K. Wang, L.T. Chow
16.33-16.44
TRANSCRIPTION FACTOR REQUIREMENT FOR E2 MEDIATED PLASMID
SEGREGATION
T Silla, A Männik, M Ustav
16.44-16.55
PAK3 INHIBITORS IDENTIFIED BY HIGH-THROUGHPUT-SCREENING AS
THERAPEUTICS FOR HPV-ASSOCIATED CANCERS
K Hellner, A Baldwin, J Xian, R Stein, M Glicksman, K Munger
16.55-17.06
RHO KINASE INHIBITION INCREASES KERATINOCYTE PROLIFERATION
AND HPV DNA REPLICATION
A McBride, S Chapman
17.06-17.17
DIFFERENTIAL METHYLATION OF HPV16-URR DURING EPITHELIAL
DIFFERENTIATION AND NEOPLASTIC TRANSFORMATION
S Vinokurova, M Reuschenbach, C Sutter, F Kommoss, D Schmidt, M von Knebel Doeberitz
17.17-17.28
COX-2 AND PGE-2 - TARGETS IN RECURRENT RESPIRATORY
PAPILLOMAS
B. Steinberg, R. Wu, A. Abramson, M Shikowitz
2009-05-12
SESSION 10: CELLULAR IMMUNOLOGY (BASIC SCIENCES)
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
08.30-09.00
ADVANCES IN MUCOSAL HPV IMMUNOLOGY
M Kast
09.00-09.10
ERADICATION OF VIN3 LESIONS BY VACCINATION WITH LONG PEPTIDES
CJM Melief, MJP Welters, ARPM Valentijn, MJG Lowik, R Offringa, JW Drijfhout, J
Oostendorp, GJ Fleuren, SH van der Burg, GG Kenter
09.10-09.20
HUMAN PAPILLOMAVIRUS TYPE-8 EARLY PROTEINS DEREGULATE
IMMUNE HOMEOSTASIS IN SKIN
S Smola, T Sperling, GP Marcuzzi, C Wickenhauser, H Pfister, S Majewski
09.20-09.30
DIRECT LONGITUDINAL COMPARISON OF T-CELL RESPONSES TO
PROPHYLACTIC HPV VACCINES.
SK Pacher, S Lucke, M Seipel, H Perlitz, T Waterboer, M Pawlita, A Schneider, AM
Kaufmann
09.30-09.40
THE ROLE OF TOLL-LIKE RECEPTORS IN HPV-16 PERSISTENCE
II Daud, ME Scott, Y Ma, S Shiboski, S Farhat, AB Moscicki
09.40-09.50
TUMOR ASSOCIATED MACROPHAGES REGULATION OF ADAPTATIVE
IMMUNITY
AP Lepique, A Bolpetti, KR Dagasthanli, IM Cuccovia
09.50-10.00
EP2R AND EP4R: CANDIDATE RECEPTORS FOR HPV16 ON LANGERHANS
CELLS
L Fahey, Wm Kast
SESSION 11: COST-EFFECTIVENESS AND MODELLING OF HPV VACCINATION
11.00-11.35
MODELLING THE EPIDEMIOLOGICAL IMPACT OF HPV VACCINES: THE
IMPACT OF ASSUMPTIONS ON RECOMMENDED STRATEGIES
G P Garnett, I Baussano
11.35-11.46
COST-EFFECTIVENESS OF HPV-16/18 VACCINATION IN A COUNTRY WITH
EFFECTIVE SCREENING.
T Westra, R Rogoza, N Ferko, H Tamming, M Drummond, T Daemen, J Wilschut, M Postma
11.46-11.57
HPV-16/18 VACCINATION IN SPAIN. HEALTH AND ECONOMIC
IMPLICATIONS ON SCREENING.
M Diaz, J.J Kim, J Ortendahl, M O’Shea, L Bruni, E Ferrer, F Bosch, S de Sanjose, S.J
Goldie
11.57-12.08
MODELING THE IMPACT OF HPV 16/18 VACCINATION ON PAP TEST
ABNORMALITIES IN THE UNITED STATES
D Datta, H Weinstock, La Koutsky, K Hsu, Er Unger, J Shlay, P Kerndt, K Ghanem, M
Hagensee, H Chesson
12.08-12.19
VIRAL TRANSMISSIBILITY AND NATURAL IMMUNITY INFERRED FROM
HPV TRANSMISSION MODELLING
JA Bogaards, M Xiridou, H de Graaf, VM Coupé, CJLM Meijer, J Wallinga, J Berkhof
12.19-12.30
DYNAMIC MODELING OF HPV VACCINE EFFECTIVENESS: IMPACT OF
PARTNERSHIP FORMATION
N Van de Velde, M Brisson, MC Boily
SESSION 12: VIRAL ATTACHMENT AND ENTRY
14.00-14.30
THE COMING OF AGE OF EXPERIMENTAL HPV INFECTIONS
M A Ozbun
14.30-14.40
INITIAL STEPS DURING IN VIVO PAPILLOMAVIRUS INFECTION
P Day, K Johnson, Rc Kines, J Roberts, C Thompson, D Lowy, J Schiller
14.40-14.50
CYCLOPHILIN-B MEDIATES CONFORMATIONAL CHANGES OF HPV16 L2
DURING INFECTIOUS ENTRY
M Bienkowska - Haba, H.D. Patel, M. Sapp
14.50-15.00
CYCLOPHILINS FACILITATE INFECTIOUS ENTRY OF HPV16
RM Schowalter, DV Pastrana, DE Anderson, P Day, CB Buck
15.00-15.10
TEMPOROSTRUCTURAL REARRANGEMENTS OF THE HUMAN
PAPILLOMAVIRUS L2 EXTERNAL LOOP
M Conway, C Meyers
15.10-15.20
COMPREHENSIVE CELL BIOLOGICAL ANALYSIS OF HPV-16 ENTRY INTO
HOST CELLS
M Schelhaas, P Day, J Schiller, A Helenius
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
15.20-15.30
CLATHRIN- AND CAVEOLIN-INDEPENDENT ENTRY OF HPV16 VIA TEMS
C Lambert, G Spoden, K Boller, L Florin
SESSION 13: HUMORAL IMMUNITY
16.00-16.30
L2 MINOR CAPSID PROTEIN-BIOLOGY AND VACCINES
R Roden
16.30-16.40
SEROLOGIC RESPONSE TO EXPERIMENTAL TRANSMISSION OF MFPV-3
IN FEMALE MACAQUES
RD Burk, Z Chen, Y Studentsov, C Wood
16.40-16.50
MULTIPLEX HUMAN PAPILLOMAVIRUS SEROLOGY BASED ON HEPARIN
COATING AND VLPS
H Faust, P Knekt, J Dillner
16.50-17.00
SEROEPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS 11, 16 AND 18 IN MEN
B Lu, R Viscidi, Y Wu, E Lazcano - Ponce, L Villa, D Smith, M Papenfuss, M Abrahamsen, A
Giuliano
17.00-17.10
DETERMINANTS OF SEROCONVERSION AMONG HPV-16/18 DNA POSITIVE
YOUNG WOMEN
C Porras, C Bennett, M Safaeian, A Hildesheim, A Rodriguez, P Gonzalez, S Wacholder, D
Solomon, Lj Van Doorn, C Bougelet, W Quint, R Herrero, M Schiffman, for the CVT Group
17.10-17.20
HPV SEROLOGY IN WOMEN FOLLOWED-UP FOR 36 MONTHS POST
PARTUM
S Syrjänen, T Waterboer, M Sarkola, Km Michael, M Rintala, K Syrjänen, S Grenman, M
Pawlita
17.20-17.30
IGA ANTIBODIES AND VIRAL LOAD IN HPV INFECTED WOMEN.
A L Combita Rojas, M Molano, P Coursaget, A Touzé, N Muñoz, Df Duarte
SESSION 14: VIRAL GENE EXPRESSION
08.30-09.05
PAPILLOMAVIRUS GENE EXPRESSION: PUZZLES AND CHALLENGES
Z-M Zheng
09.05-09.16
ESTABLISHMENT OF TRANSCRIPTION FROM INCOMING VIRAL GENOME
REQUIRES L2 PROTEIN
M. Sapp, L. Hilbig, M Bienkowska - Haba
09.16-09.27
ASF/SF2 AND SRP30C REGULATE HPV-16 EARLY AND LATE MRNA
SPLICING
M Somberg, X Li, S Schwartz
09.27-09.38
P300 NOT CBP ENHANCES HPV TRANSCRIPTION BY DISTINCT AP-1
COMPLEXES
W-M Wang, A Lee, S-y Wu, C-M Chiang
09.38-09.49
FUNCTIONAL MAPPING OF THE HUMAN PAPILLOMAVIRUS TYPE 16 E1
CISTRON
TH Haugen, MJ LACE, JR Anson, LP Turek
09.49-10.00
A REPORTER SYSTEM TO STUDY HVP SPLICING
J.l Gonzalez - Montoya, M Guido, A Garcia - Carrancá
SESSION 15: CUTANEOUS HPV INFECTIONS AND SKIN CANCER
11.00-11.11
PROSPECTIVE STUDY OF HPV SEROPOSITIVITY AND NON-MELANOMA
SKIN CANCER
K Andersson, Km Michael, T Waterboer, T Luostarinen, R Gislefoss, O Forslund, T
Hakulinen, M Pawlita, J Dillner
11.11-11.22
HPV SEROPREVALENCE IN EPIDERMODYSPLASIA VERRUCIFORMIS
PATIENTS, HEALTHY RELATIVES AND CONTROLS
Km Michael, T Waterboer, H Pfister, M. Gariglio, S Majewski, M Favre, M Pawlita
11.22-11.33
INDICATIONS FOR AN ASSOCIATION OF HIGH BETAPV-LOADS WITH SKIN
CARCINOGENESIS
SJ Weissenborn, R Neale, D Abeni, JN Bouwes Bavinck, MCW Feltkamp, A Green, M De
Koning, U Wieland, H Pfister, and EPI-HPV-UV-CA group
11.33-11.44
CLASSIFICATION OF CUTANEOUS HPV-TYPES WITH RESPECT TO THEIR
IMMORTALIZATION CAPACITY
RDM Steenbergen, D Claassen - Kramer, CJLM Meijer, L Struijk, PZ van der Meijden, MCW
Feltkamp, PJ Snijders
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
11.44-11.55
HPV20E6 ONCOPROTEIN MODIFIES EPITHELIAL DIFFERENTIATION AND
INDUCES LIPID ACCUMULATION
E Herráez - Hernández, R Nobre, L Langbein, S Kaden, H-J Gröne, Em de Villiers
11.55-12.06
MASTOMYS COUCHA: A MODEL FOR PV-INDUCED PATHOGENESIS OF
THE SKIN
K Schaefer, T Waterboer, M Mueller, J Nafz, I Nindl, F Roesl
12.06-12.17
IDENTIFICATION OF B-CELL EPITOPES ON VLPS OF CUTANEOUS
SPECIES ALPHA-HPVS
T Senger, Mr Becker, L Schädlich, T Waterboer, Cb Buck, L Gissmann
12.17-12.28
MERKEL-CELL-POLYOMAVIRUS IS PREVALENT IN SKIN AND MUCOSA
INDEPENDENT OF HPV-STATUS
U Wieland, C Mauch, A Kreuter, T Krieg, SJ Weissenborn, H Pfister
SESSION 16: HPV AMONG THE HIV INFECTED
14.00-14.11
SCREEN-AND-TREAT USING HPV TESTING IS HIGHLY EFFECTIVE AMONG
HIV-INFECTED WOMEN
L Kuhn, L Denny, M DeSousa, T Wright
14.11-14.22
SAFETY AND IMMUNOGENICITY OF GARDASIL® IN HIV-INFECTED
CHILDREN
AB Moscicki, A Weinberg, L-Y Song, E Handelsman, J Patterson, A Saah, D Radley, JS
Read, C Sattler, M Levin
14.22-14.33
HLA ASSOCIATIONS WITH HPV/SIL DECREASE WITH
IMMUNOSUPPRESSION IN HIV-POSITIVE WOMEN
H Strickler, M Martin, X Xue, Rd Burk, A Hildesheim, H Minkoff, L. S Massad, K Anastos, A
Kovacs, M Fazzari, G D'Souza, T Harris, M Young, V Bonagura, J Palefsky, M Carrington
14.33-14.44
HIGH EXPRESSION PROTEINS IN HIV/HPV CO-INFECTED WOMEN
A Nicol, G Nuovo, B Grinsztejn, A Pires, S Souza, A Tristão, F Russomano, L Velasque, K C
Pessanha, J R Lapa e Silva, C Pirmez
14.44-14.55
HIV AFFECTS HPV CONCORDANCE AND VIRAL LOAD IN COUPLES
Z Z.A Mbulawa, D Coetzee, D Marais, I Gustavsson, M Hoffman, U Gyllensten, Al Williamson
14.55-15.06
RISK OF HPV-ASSOCIATED CANCERS AMONG PERSONS WITH AIDS
A Chaturvedi, Mm Madeleine, R Biggar, E Engels
15.06-15.17
ARE EXTIRPATIVE PROCEDURES FOR CIN EFFECTIVE IN HIV-POSITIVE
WOMEN?
Ll Reimers, D Daniel, S Sotardi, L G Chiu, A Van Arsdale, D L Wieland, J M Leider, D J
Gerry, D Gupta, G L Goldberg, H Strickler, Mh Einstein
15.17-15.30
TYPE-SPECIFIC CERVICO-VAGINAL HPV INFECTION INCREASES RISK OF
FEMALE HIV ACQUISITION
K.K. Smith - McCune, S. Shiboski, Z. M. Chirenje, T. Magure, J. Tuveson, Y. Ma, M.
DaCosta, A.-B. Moscicki, J. Palefsky, R. Mutasa, T. Chipato, A. van der Straten, G.F.
Sawaya, ,
SESSION 17: HPV AND HEAD & NECK CANCERS
16.00-16.13
HPV16 E6 INDUCED PTPN13 LOSS ENHANCES ONCOGENE RELATED
MAPK SIGNALING
J Lee
16.13-16.24
ORAL HPV PREVALENCE AMONG HEALTHY MEN INTERNATIONALLY
AR Kreimer, A Hildesheim, M Abrahamsen, D Smith, LL Villa, E Lazcano, A Giuliano
16.24-16.35
MESENCHYMAL TRANSFORMATION DURING TUMOR PROGRESSION IN
HPV-RELATED OROPHARYNGEAL CANCER
EJ Speel, M Stenner, B Yosef, C Huebbers, SF Preuss, HP Dienes, JP Klussmann, M
Odenthal
16.35-16.46
HUMANA PAPILLOMAVIRUS IN TONSILLAR CANCER, AN EPIDEMIC OF
VIRAL CARCINOMA
T Dalianis, A Näsman, P Attner, L Hammarstedt, J Du, M Eriksson, G Giraud, S Ährlund -
Richter, L Marklund, D Lindquist, M Romanitan, T Ramqvist, J Lindholm, P Sparen, W Ye, H
Dahlstrand, E Munck - Wikland
16.46-16.57
HPV INFECTION IS ABSENT FROM ESOPHAGEAL CANCER IN CHINA
W Wei, J Koshiol, W Chen, Ar Kreimer, J Wang, P Gravitt, J Ren, C C Abnet, F Kamangar, M
Gillison, M J Roth, P Zhao, Pe Castle, G Wang, P R Taylor, Z Dong, S M Dawsey, Y Qiao
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
16.57-17.08
ASSOCIATION BETWEEN CHROMOSOME STABILITY, HPV AND
PROGNOSIS IN TONSILLAR CARCINOMA
JJ Mooren, SMH Claessen, A Haesevoets, Ahn Hopman, Fcs Ramaekers, JP Klussmann, JJ
Manni, B Kremer, EJM Speel
17.08-17.19
ADENOID-CYSTIC CARCINOMAS OF SALIVARY GLANDS ARE
ASSOCIATED WITH HIGH-RISK HPV
AE Albers, C Chen, M Hummel, E Glastetter, U Keilholz, AM Kaufmann
17.19-17.30
NATURAL HISTORY OF ORAL AND ANAL HPV INFECTION.
G D´ Souza, E Sugar, M Gillison
2009-05-13
SESSION 18: TRANSFORMATION AND CARCINOGENESIS
08.30-09.05
ROLES OF VIRAL AND HOST FACTORS IN CERVICAL CANCER
P Lambert
09.05-09.16
MODULATION OF P63 IN CERVICAL CARCINOMA AND REGULATION BY E6
F Thierry, Y Ben Khalifa, M M Tan, D S Toh, S Teissier, M Daynac
09.16-09.27
CUTANEOUS HPV38 INDUCES STABILIZATION OF DELTANP73ALPHA BY
A NOVEL MECHANISM
r accardi
09.27-09.38
ONCOGENE DISRUPTION OF CELL-CELL SENSING UNDERLIES
PHENOTYPIC CHANGE DURING NEOPLASIA
J Doorbar, Erin Isaacson, Ken Raj, Q Wang, D Jackson
09.38-09.49
INDUCTION OF GENOMIC INSTABILITY BY THE HPV16 E7 ONCOPROTEIN
I Hoffmann, R Bahtz, M Arnold, A Krause, O Cizmecioglu, F Settele
09.49-10.00
IDENTIFICATION AND FUNCTIONAL INVESTIGATION OF GENES INVOLVED
IN CERVICAL CARCINOGENESIS
M Liesenfeld, B. Rudolph, D Steinbach, L Jansen, S. Mosig, H. Funke, I Runnebaum, M
Dürst, C Backsch
SESSION 19: TREATMENT AND POST-TREATMENT FOLLOW-UP
11.00-11.11
DEVELOPING OPTIMUM FOLLOW-UP STRATEGIES AFTER CIN
TREATMENT; A SCORING SYSTEM(FUSS)
M Kyrgiou, G Koliopoulos, I Tsoumpou, P Martin - Hirsch, M Arbyn, E Paraskevaidis
11.11-11.22
HC2 AS TEST OF CURE IN STAGE IA CERVICAL CANCER
M Sideri, S Costa, S Boveri, C Casadio, M Sandri, N Spolti, G Negri
11.22-11.33
LONG-TERM INCIDENCE/MORTALITY OF CERVICAL OR VAGINAL
CANCER AFTER CIN3-TREATMENT
B Strander, J Hällgren, P Sparén
11.33-11.44
MORTALITY AFTER TREATMENT OF CERVICAL INTRAEPITHELIAL
NEOPLASIA
I Kalliala, T Dyba, P Nieminen, T Hakulinen, A Anttila
11.44-11.55
POST-TREATMENT HPV TESTING AND LONG-TERM RISK AT
RECURRENCE
M Kocken, JA Louwers, WA ter Harmsel, J Berkhof, PJ Snijders, RHM Verheijen, T
Helmerhorst, CJLM Meijer
11.55-12.06
HPV TESTING IN THE FOLLOW-UP AFTER CONIZATION
A Trope, K Sjøborg, A Eskild, T Eriksen, C Jonassen, U Westerhagen, AK Lie
12.06-12.17
HPV TEST OF CURE REMAINS HIGHLY PREDICTIVE AT 5YRS FOLLOW-UP
H Kitchener, C Moore, R Hadwin, L Nelson, P Walker, A Sargent, J Wood, GB Anthony, M
Cruickshank
12.17-12.28
SURVEILLANCE AFTER TREATMENT FOR CIN: HPV TESTING IS NOT
COST-EFFECTIVE
J Melnikow, S Kulasingam, M Kuppermann, LJ Helms, C Slee, G Sawaya
SESSION 20: HPV-BASED SCREENING I
14.00-14.13
FOLLOW-UP OF THE NTCC RANDOMISED CONTROLLED TRIAL.
G Ronco, N Segnan, A Gillio - Tos, R Rizzolo, A Del Mistro, M Zorzi, P Dalla Palma, F
Carozzi, C Naldoni, M Confortini, P Pierotti, P Giorgi Rossi, J Cuzick
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
14.13-14.24
DURABLE BENEFITS OF HPV-BASED SCREEN-AND-TREAT TO 36 MONTHS
T Wright, L Denny, M DeSousa, L Kuhn
14.24-14.35
HART: LONG-TERM FOLLOW-UP AMONG WOMEN SCREENED BY
CYTOLOGY AND HPV TESTING
J Cusick, D Mesher, A Szarewski, L Cadman, H Cubie, G Hulman, H Kitchener, D Luesley, U
Menon, G Terry, M Desai, C Gie, L Ho, C Pickles, P Sasieni
14.35-14.46
COST-EFFECTIVENESS OF HPV DNA SCREENING IN NON-VACCINATED
AND VACCINATED WOMEN
J Berkhof, VM Coupé, JA Bogaards, Fj van Kemenade, PJ Snijders, CJlm Meijer
14.46-14.57
COST-EFFECTIVENESS OF VARIOUS CERVICAL SCREENING MODALITIES
IN RURAL CHINA
K Canfell, JF Shi, Y Ning, JB Lew, R Legood, FH Zhao, YJ Kang, L Ma, L Simonella, M
Smith, YZ Zhang, JF Chen, M Clements, G Clifford, S Francheschi, Y Qiao
14.57-15.08
ADDITION OF HRHPV TESTING TO CONVENTIONAL CYTOLOGICAL
SCREENING: VUSA-SCREEN TRIAL
D Rijkaart, J Berkhof, PJ Snijders, CJLM Meijer
15.08-15.19
AGE-SPECIFIC PERFORMANCE OF HPV DNA TEST IN PRIMARY CERVICAL
SCREENING
A Anttila, M Leinonen, P Nieminen, L Kotaniemi - Talonen, N Malila, J Tarkkanen, P Laurila
15.19-15.30
HPV TESTING CAN EXTEND SCREENING INTERVALS; EVIDENCE FROM
ARTISTIC TRIAL.
C Thomson, H Baysson, M Almonte, M Desai, A Sargent, A Turner, A Bailey, J Peto
SESSION 21: HPV-BASED SCREENING II
15.30-15.40
PREVENTION BY OFFERING HRHPV-TESTING ON SELF-SAMPLED
CERVICOVAGINAL SPECIMENS TRIAL (PROHTECT)
M Gök, DAm Heideman, FJ Van kemenade, L Rozendaal, J Berkhof, PJ Snijders, CJLM
Meijer
15.40-15.50
NATURAL HISTORIES OF HPV DEFINED BY SELF-SAMPLING
AB Moscicki, L Widdice, Y Ma, S Farhat, S Miller - Benningfield, J Jonte, J Jay, C Godwin -
de Medina, E Hanson, L Clayton, J Simington, S Shiboski
15.50-16.00
TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS (HPV) STRATIFIED BY
ENDOCERVICAL AND VAGINAL SELF-TEST
RG Pretorius, Y Qiao, JL Belinson, H Wang, J Smith, J Li, F Taddeo, S Hu, RJ Burchette
16.00-16.10
TYPING FOR TRIAGING HPV POSITIVE WOMEN AND EXPECTED
VACCINATION EFFECT
F Carozzi, G Ronco, A Del Mistro, L De Marco, S Girlando, M Zorzi, P Dalla palma, C
Naldoni, M Confortini, P Giogi Rossi, J Cuzick, R Rizzolo, N Segnan, A Gillio - Tos
16.10-16.20
HPV TESTING AND CYTOLOGY IN PRIMARY SCREENING IN RURAL CHINA
FH Zhao
16.20-16.30
TRIAGE OF ASCUS/LSIL: META-ANALYSIS OF HPV TEST POSITIVITY RATE
M Arbyn, P Martin - Hirsch, F Buntinx, E Paraskevaidis
SESSION 22: ACCEPTABILITY, BEHAVIOURIAL AND PSYCHOLOGICAL ASPECTS OF K1-3
SCREENING AND VACCINATION
08.30-08.43
COLPOSCOPY AFTER CERVICAL DYSPLASIA: PSYCHOLOGICAL
ASPECTS
C Hellsten, K Sjöström, P Lindqvist
08.43-08.54
U.S. PHYSICIANS’ RECOMMENDATIONS ON SCREENING INTERVALS AND
HPV DNA TESTING
M Saraiya, Z Berkowitz, R Yabroff, V Benard, L Wideroff, S Kobrin
08.54-09.05
ASCCP GUIDELINE ADHERENCE ON MANAGEMENT OF DISCORDANT AND
ASCUS/HPV - RESULTS
M Saraiya, Z Berkowitz, V Benard, L Wideroff, S Kobrin
09.05-09.16
ATTITUDES TO HPV VACCINATION AMONG PARENTS TO CHILDREN 12-15
YEARS
P Sparén, C Young, C Lundholm, T Tran, L Arnheim Dahlström
09.16-09.27
SOCIO-CULTURAL ISSUES FOR INTRODUCTION OF HPV VACCINE IN
LOW-RESOURCE SETTINGS
DS LaMontagne, A Bingham, JK Drake, L Menezes
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
09.27-09.38
EARLY UPTAKE OF HPV VACCINATION IN GERMANY
SJ Klug, M Claus, A Ahmad, J König, M Blettner
09.38-09.49
RISK PERCEPTIONS AFTER HPV VACCINATION
JA Kahn, SL Rosenthal, C Morrow, M Shew, DI Bernstein, GD Zimet
09.49-10.00
CHALLENGES OF DELIVERING SCHOOL-BASED HPV VACCINATION IN
MANCHESTER, UK
L Brabin, S Roberts, R Stretch, D Baxter, G Chambers, H Kitchener, R McCann
SESSION 23: TRANSFORMATION AND CARCINOGENESIS II
11.00-11.13
CELLULAR ZINC HOMEOSTASIS AS A NATURAL ANTI-HPV BARRIER
M Lazarczyk, P Cassonnet, C Pons, Y Jacob, M Favre, M Lazarczyk, m Lazarczyk
11.13-11.24
NFX1-123 INCREASES HTERT POST-TRANSCRIPTIONALLY IN HPV 16E6-
KERATINOCYTES
R Katzenellenbogen, P Vliet, D Galloway
11.24-11.35
PI3K SIGNALLING DURING HPV MEDIATED TRANSFORMATION IN VITRO
Fe Henken, Pj Snijders, Cjlm Meijer, Rdm Steenbergen
11.35-11.46
PHOSPHORYLATION OF HSCRIB REGULATES ITS INTERACTION WITH
HPV E6 ONCOPROTEINS.
K Nagasaka, L Banks
11.46-11.57
DOWN-MODULATION OF THE P53-NOTCH1 PATHWAY BY HPV-16 E6
T Yugawa, M Narisawa - Saito, M Fujita, T Kiyono
11.57-12.08
IDENTIFICATION OF THE NUCLEAR TRANSPORT SIGNALS OF HPV16 E7
ONCOPROTEIN
J Moroianu, A Knapp, P McManus, K Bockstall, Z Piccioli
12.08-12.19
CUTANEOUS HPV38E7 INTERACTS WITH HUMAN EEF1A AND
MODULATES ITS FUNCTIONS
B Sylla, J. Yue, I. Zanella - Cleon, R. Accardi - Gheit, I. Hussain, M. Becchi, E Oswald, A
Alonso, M Tommasino
12.19-12.30
HPV-16 INFECTION ALTERS CELLULAR MICRORNA EXPRESSION IN
SCCHN
AI Boster, RL Ferris, SA Khan
SESSION 24: VIRAL PROTEINS: STRUCTURE AND FUNCTION
14.00-14.11
HPV18 E2 PROTEIN STABILITY IS CELL-CYCLE DEPENDENT
S Bellanger, C L Tan, W L Nei, P He, F Thierry
14.11-14.22
POST-TRANSLATIONAL MODIFICATION REGULATES HPV16 E1^E4
PROTEIN STRUCTURE AND FUNCTION
J Khan, P McIntosh, C Davy, S Hinz, J Doorbar
14.22-14.33
MODIFICATION OF HPV18 E1^E4 BY PROTEOLYSIS,CDK AND PKA
PHOSPHORYLATION.
A Pugh, G KNIGHT, I BELL, S ROBERTS
14.33-14.44
UP-REGULATION OF P18INK4C EXPRESSION BY HPV E6 VIA P53-MIR-34A
PATHWAY
X Wang, Z-m Zheng
14.44-14.55
INTERACTION OF THE E8^E2C REPRESSOR-PROTEIN WITH THE
CELLULAR CHD6 PROTEIN
J Fertey, T Iftner, F Stubenrauch
14.55-15.06
USE OF A LUCIFERASE FUSION TO STUDY HPV E2 DEGRADATION
D Gagnon, S Joubert, H Sénéchal, A Fradet - Turcotte, S Torre, J Archambault
15.06-15.17
INTERACTION OF BETA PAPILLOMAVIRUS E2 TETHERING PROTEINS
WITH MITOTIC CHROMOSOMES
A McBride, A Poddar, V Sekhar
SESSION 25: PROPHYLACTIC VACCINES (BASIC SCIENCES)
15.20-15.31
IN VIVO MECHANISMS OF PROTECTION BY VLP AND L2 VACCINATION
J Schiller, RC Kines, C Thompson, S Jagu, R Roden, D Lowy, P Day
15.31-15.42
STRUCTURAL AND IMMUNOLOGIC ANALYSIS OF DIFFERENTLY MODIFIED
HPV16 L1 CAPSOMERES
L Schädlich, B Gerlach, T Senger, N Mücke, C Klein, I Bravo, M Müller, L Gissmann
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
15.42-15.53
HPV16 ANTIBODY EPITOPES FROM VACCINE RECIPIENTS AND
FOLLOWING NATURAL INFECTIONS
GC Wipf, JJ Carter, LA Koutsky, D Galloway
15.53-16.04
ANTIBODY RESPONSES IN ORAL FLUID AND SERUM FOLLOWING HPV
VACCINATION
JJ Carter, A Rowhani - Rahbar, Se Hawes, Jp Hughes, La Koutsky, d Galloway
16.04-16.15
RECOGNITION PATTERN OF NEUTRALIZING AND NON-NEUTRALIZING
ANTI-L2 ANTIBODIES
M Müller, A Bolchi, M Tommasino, S Ottonello, I Rubio
16.15-16.26
CHIMERIC L1/L2 VIRUS-LIKE PARTICLES (VLP) AS POTENTIAL BROAD-
SPECTRUM HPV VACCINES
C Schellenbacher, R Roden, R Kirnbauer
2009-05-14
SESSION 26: MOLECULAR MARKERS & HPV TESTING METHODS
08.30-08.40
DIAGNOSTIC HPV16 RNA PATTERN DISCRIMINATING MILD AND SEVERE
CERVICAL LESIONS
M Schmitt, V Dalstein, T Waterboer, C Clavel, L Gissmann, M Pawlita
08.40-08.50
CAN IMMUNOHISTOCHEMISTRY FIX THE DIAGNOSTIC INTERPRETIVE
PROBLEMS WITH CERVICAL BIOPSIES?
M Stoler, K Atkins, M Galgano, W Brix, S Nassau, P Castle
08.50-09.00
E6/E7 MRNA AND DNA TESTS FOR DETECTION OF ≥CIN II
S Ratnam, F Coultee, D Fontaine, J Bentley, N Escott, P Ghatage, G Holloway, E Bartellas,
N Kum, C Giede, V Gadag, A Lear
09.00-09.10
COMPARISON OF MEASURES OF VIRAL PERSISTENCE TO PREDICT
SUBSEQUENT DISEASE
J Gage, M Schiffman, D Solomon, P Castle
09.10-09.20
ABSOLUTE RISK OF SUBSEQUENT CIN3+ ACCORDING TO DIFFERENT
HPV TYPES
S Kjær, C Munk, K Frederiksen, J Junge, T Iftner
09.20-09.30
AMPLICOR HPV DETECTION IN THE ASCUS-LSIL TRIAGE STUDY
N Wentzensen, P Gravitt, D Solomon, C Wheeler, PE Castle
09.30-09.40
EVALUATION OF ABBOTT HIGH RISK HPVDNA ASSAY IN PRIMARY HPV-
SCREENING
B Hammas, J Dillner, C Wahlström
09.40-09.50
P16INK4A IN CERVICAL CYTOLOGY AND HISTOLOGY: SYSTEMATIC
REVIEW AND META-ANALYSIS
I Tsoumpou, M Arbyn, M Kyrgiou, N Wentzensen, G Koliopoulos, P Martin - Hirsch, V
Malamou - Mitsi, E Paraskevaidis
09.50-10.00
DIGENE HPV GENOTYPING LQ-TEST: HIGH-THROUGHPUT GENOTYPING
USING XMAP TECHNOLOGY
D Geraets, DAM Heideman, M de Koning, PJ Snijders, DCJG van Alewijk, CJLM Meijer, Lj
van Doorn, W Quint
SESSION 27: HPV INFECTION IN MALES
11.00-11.11
QUADRIVALENT HPV VACCINE EFFICACY IN MEN HAVING SEX WITH MEN
J Palefsky, A Giuliano
11.11-11.22
CORRELATES OF PERSISTENT INCIDENT GENITAL HPV INFECTION IN
YOUNG MEN
Y Arima, J Partridge, R Winer, S-K Lee, Q Feng, Jp Hughes, M Stern, S O’Reilly, La Koutsky
11.22-11.33
HPV IN DANISH MEN. ASSOCIATION WITH CIRCUMCISION-STATUS AND
GENITAL WARTS
S Kjær, C Munk, B Nøhr, A Nielsen, K Liaw, T Iftner
11.33-11.44
PROBABILITY OF HPV TRANSMISSION AMONG NEWLY-FORMED
COUPLES
A Burchell, J Hanley, P Tellier, F Coutlée, E Franco
11.44-11.55
CONDOM USE IS ASSOCIATED WITH LOWER HPV PREVALENCE IN MEN
CM Nielson, RB Harris, A Nyitray, EF Dunne, KM Stone, A Giuliano
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
11.55-12.06
INTERNATIONAL HPV INCIDENCE AMONG MEN AGES 18-70 YEARS
A Giuliano, JH Lee, WJ FULP, LL Villa, E Lazcano, M Papenfuss, D Smith, M Abrahamsen
12.06-12.17
CONDOMS PREVENT INCIDENT ANAL HUMAN PAPILLOMAVIRUS
INFECTION IN MEN
P Chin - Hong, E Vittinghoff, D Benet, S Buchbinder, M Da Costa, T Darragh, F Judson, B
Koblin, K Mayer, J Palefsky
12.17-12.28
HIGH ANAL HPV PREVALENCE IN MULTINATIONAL SAMPLES: THE HIM
STUDY
A Nyitray, D Smith, L Villa, E Lazcano - Ponce, M Abrahamsen, A Giuliano
SESSION 28: BEST POSTER LECTURES
13.30-13.40
BEST POSTER AWARDS
13.40-13.50
BEST POSTER AWARD LECTURE NUMBER 1
to be annonunced
13.50-14.00
BEST POSTER AWARD LECTURE NUMBER 2
to be annonunced
SESSION 29: LATE BREAKER ABSTRACTS
14.00-14.10
CROSS-PROTECTIVE EFFICACY OF CERVARIX™ AGAINST ONCOGENIC
HPV TYPES BEYOND HPV-16/18.
R Skinner, D Apter, SN Chow, C Wheeler, G Dubin, for the HPV PATRICIA Study Group
14.10-14.20
RAPID DECLINE IN WARTS AFTER NATIONAL QUADRIVALENT HPV
VACCINE PROGRAM
C Fairley, J Hocking, M Chen, B Donovan, C Bradshaw
14.20-14.30
DEFICIENCY IN THE FANCOMNI ANEMIA PATHWAY SENSITIZES MICE TO
HPV-ASSOCIATED HEAD AND NECK CANCER
J W Park, K Strati, P Lambert
14.30-14.40
ARE 2 DOSES OF HPV VACCINE ADEQUATE IN GIRLS ?
S Dobson, M Dawar, D Scheifele, T Kollmann, S McNeil, S Halperin, J Langley, M Dionne,
M-E Picard, C Sauvageau, M Krajden, F Marra, D Miller, D Money, M Naus, G Ogilvie, J
Singer, J Bettinger, E Young
14.40-14.50
CERVICAL CANCER AMONG IMMIGRANTS IN SWEDEN, FROM 1968
THROUGH 2004
F Azerkan, K Zendehdel, P Tillgren, E Faxelid, P Sparén
14.50-15.00
FINAL PHASE III EFFICACY ANALYSIS OF CERVARIX™ IN YOUNG WOMEN
J Paavonen, P Naud, J Salmerón, C Wheeler, S-N Chow, D Apter, H Kitchener, X
Castellsague, J Teixeira, SR Skinner, J Hedrick, U Jaisamrarn, G Limson, SM Garland, A
Szarewski, B Romanowski, F Aoki, T Schwarz, WAJ Poppe, X Bosch, D Jenkins, K Hardt, T
Zahaf, D Descamps, F Struyf, M Lehtinen, G Dubin
SESSION 30: GLOBAL HPV EPIDEMIOLOGY
08.30-08.41
COMPARISON OF SERA AND DRIED BLOOD SPOTS FOR HPV
SEROEPIDEMIOLOGY
T Waterboer, B Dondog, KM Michael, A Michel, M Schmitt, S Franceschi, G Clifford, M
Pawlita
08.41-08.52
CUMULATIVE 2-YEAR HR-HPV PERSISTENCE AND ACQUISITION IN PERI-
URBAN INDIAN WOMEN
P Gravitt, H Vedantham, P Paul, B Kalpana, D Vidyadhari, P Sowjanya, G Ramakrishna, K
Vijayaraghavan, K Shah
08.52-09.03
SEROPREVALENCE OF HPV 6, 11, 16, 18 IN UNITED STATES
Le Markowitz, M Sternberg, Ef Dunne, Er Unger
09.03-09.14
AGE-SPECIFIC PREVALENCE OF PRECANCEROUS LESIONS OF THE
CERVIX: GLOBAL REVIEW
J Ting, DT Kruzikas, J Smith
09.14-09.25
WORLDWIDE HPV TYPE-SPECIFIC PREVALENCE IN CYTOLOGICALLY
NORMAL WOMEN (1995-2008)
L Bruni, E Ferrer, M Diaz, KS Louie, G Albero, J Muñoz, X Castellsagué, F Bosch, S de
Sanjosé
09.25-09.36
HPV 16 AND 18 NEUTRALIZING ANTIBODY IN PRENATAL WOMEN
M Krajden, K Karunakaran, S So, J Palefsky, R Sharma, A Yu, R Chow, S Dobson, G
Ogilvie, M Petric
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
09.36-09.47
HIGH-RISK HPV PERSISTENCE IN DANISH WOMEN FROM THE GENERAL
POPULATION
A Nielsen, S Kjær, C Munk, M Osler, T Iftner
09.47-09.58
POPULATION-BASED SEROPREVALENCE OF HUMAN PAPILLOMAVIRUS
IN CHINESE WOMEN
J Ji, H Wang, W Chen, s Hu, M Esser, C. Velicher, JL Belinson, Rg Pretorius, J Smith, Y
Qiao
SESSION 31: HPV TESTING II
11.00-11.10
THE WHO HPVLABNET INTERNATIONAL PROFICIENCY STUDY OF
HPVDNA TYPING METHODS
C Eklund, T Zhou, J Dillner, and the WHO HPV Laboratory Network
11.10-11.20
NATIONAL QUALITY ASSURANCE PROGRAM FOR HPV-TESTING AND
TYPING IN ITALY
F Carozzi, G Venturini, L Ciccocioppo, A Del Mistro, A Gillio - Tos, S Girlando, L De Marco, H
Frayle, P Giorgi Rossi, G Ronco, M Confortini, C Tufi, C Sani, HPV QA Working Group
11.20-11.30
TRANSCRIPTOME PROFILING OF CERVICAL SWABS FROM
PERSISTENTLY HPV16 INFECTED WOMEN
A Manawapat, S Krüger Kjaer, B Schopp, R Russ, A-M Florea, C Munk, T Iftner, F
Stubenrauch
11.30-11.40
KALLICREIN-7 AND SUPEROXIDE DISMUTASE-2 AS PROGRESSION
MARKERS OF CERVICAL DISEASE
L Termini, PC Maciag, FA Soares, S Nonogaki, VAF Alves, A Longatto - Filho, LL Villa
11.40-11.50
TRIAGE OF ASC-US AND LSIL CYTOLOGY CASES BY P16
IMMUNOCYTOCHEMISTRY
C BERGERON, D KARIN, K PETRA, T MARCUS, R RUDIGER
11.50-12.00
THE USE OF AN RNA-BASED HPV-TEST IN HPV TRIAGING
SW Sørbye, S Fismen, T Gutteberg, ES Mortensen
12.00-12.10
RESULTS OF THE FRENCH APTIMA HPV SCREENING EVALUATION (FASE
STUDY)
J Monsonego, P Halfon, L Zerat, M Ricart, F Ruiz, k Syrjänen
12.10-12.20
A NOVEL BROAD-SPECTRUM PCR-LUMINEX ASSAY FOR IDENTIFICATION
OF WART HPV
M de Koning, J ter Schegget, M Kamp, B Kleter, Mcw Feltkamp, J Eekhof, JN Bouwes
Bavinck, K Purdie, C Harwood, W Quint
12.20-12.30
HPV MRNA AND P16INK4A AS TRIAGE MARKERS IN CERVICAL
CYTOLOGY
M Reuschenbach, A Clad, C von Knebel Doeberitz, J Rahmsdorf, R Grote, L Wu, N
Wentzensen, M von Knebel Doeberitz
SESSION 32: TAXONOMY AND HPV DATABASES
13.30-13.43
PAPILLOMAVIRUS TAXONOMY: REPORT OF THE ICTV STUDY GROUP.
H.U. Bernard, Rd Burk, Em de Villiers, M. van Ranst, H. zur Hausen
13.43-13.54
PAPILLOMAVIRUS EPISTEME (PAVE): A COMPREHENSIVE
PAPILLOMAVIRIDAE DATABASE AND ANALYSIS RESOURCE
Y. Huyen, Y. Mohamoud, V. Gopalan, S. Bandaru, J. Nozzi, J. Barnett, A McBride
13.54-14.05
CHARACTERIZATIONS OF NINE MACACA FASCICULARIS
PAPILLOMAVIRUS (MFPV) COMPLETE GENOMES
K van Doorslaer, Z Chen, C Wood, Rd Burk
14.05-14.16
MODELING CARCINOGENIC HPV GENITAL INFECTIONS AND DISEASE
WITH RHPV1
M Ozbun, J. Maestas, A. Maldonado, N. Patterson, M. Kivitz, N. Joste, P. Marx, V. Traina -
Dorge
14.16-14.27
NOVEL HPV SEQUENCES IN CERVICAL CARCINOMA CONTAINING SINGLE
HPV GENOTYPES
W Quint, D Geraets, N Guimerà, N Guimerà, M de Koning, LJ van Doorn, S de Sanjosé, F
Bosch
14.27-14.38
ALPHA AND BETA PAPILLOMAVIRUSES DIFFER IN SYNONYMOUS CODON
USAGE
N Cladel, A Bertotto, N Christensen,
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
14.38-14.49
EVOLUTION OF PRIMATE ALPHA PAPILLOMAVIRUSES
Z Chen, K van Doorslaer, R DeSalle, C Wood, Rd Burk
14.49-15.00
TOWARDS A TIME SCALE FOR THE EVOLUTION OF PAPILLOMAVIRUSES
I Bravo, A Stamatakis, O Bininda - Emonds, M Göker, I Nindl, M Gottschling

Source: http://www.hpv2009.org/PresentationProgram090324.pdf